8-K: RespireRx Pharmaceuticals Enters Agreements for NIH Grant Application Support

RespireRx Pharmaceuticals has engaged Alien Technology Transfer to assist with securing NIH funding for its GABAkines program, focusing on Phase II grant applications.

Summary

• RespireRx Pharmaceuticals has signed two new service agreements with Alien Technology Transfer, replacing previous agreements from July 2, 2024.
• The agreements are focused on securing funding from the National Institutes of Health (NIH) for RespireRx's EndeavourRxs GABAkines program.
• One agreement with ATT India covers services related to identifying and applying for NIH funding, specifically targeting SBIR/STTR Phase II grants.
• The other agreement with ATT US provides Technical and Business Assistance (TABA) services, including regulatory affairs consulting, IP management, and accounting services, contingent on RespireRx receiving a Phase II grant.
• The agreement with ATT India includes success-based fees of 10% of the award amount, plus a $15,000 support fee for Phase II.
• The agreement with ATT US includes a $50,000 fee for TABA services and monthly fees ranging from $2,400 to $3,200 for other services during Phase II.
• The NIH Phase II budget is estimated to be $2,045,816 for a project timeline between 1 and 3 years.

Sentiment

Score: 7

Explanation: The document indicates a positive step for the company in pursuing non-dilutive funding, but the success is not guaranteed. The agreements are structured in a way that aligns incentives, but there are still risks involved.

Positives

• The agreements provide RespireRx with expert assistance in navigating the complex NIH grant application process.
• The success-based fee structure aligns the interests of RespireRx and Alien Technology Transfer.
• The TABA services offered by ATT US can provide valuable support in regulatory affairs, IP management, and accounting.
• The focus on Phase II grants could lead to significant funding for the GABAkines program.

Negatives

• There is no guarantee that RespireRx will receive an NIH grant.
• The fees for TABA services and other support could be substantial if the company is successful in securing a grant.
• The agreements include termination fees if RespireRx decides to end the contracts early.

Risks

• The success of the project is dependent on securing NIH funding, which is a competitive process.
• Delays in the application process or changes in NIH rules could impact the project.
• The company is reliant on external consultants for key aspects of the grant application and project management.
• There are termination fees if the company decides to end the contracts early.

Future Outlook

The company is focused on securing NIH funding for its GABAkines program through the SBIR/STTR program, with the initial application submission targeted for August 28, 2024. The company will also be working with Alien Technology Transfer to manage the project and comply with all requirements.

Industry Context

This announcement reflects a common strategy for small pharmaceutical companies to seek non-dilutive funding through government grants like the NIH SBIR/STTR program. This is a competitive space, and success depends on the quality of the application and the scientific merit of the project.

Comparison to Industry Standards

• Many small biotech companies rely on NIH grants for early-stage funding, making this a standard practice in the industry.
• The success-based fee structure with Alien Technology Transfer is a common arrangement in the grant consulting space.
• The estimated Phase II budget of $2,045,816 is within the typical range for NIH SBIR/STTR grants.
• Companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals have also utilized government funding in their early stages, although they are now much larger and more established.

Stakeholder Impact

• Shareholders may view this as a positive step towards securing funding for the company's research programs.
• Employees may benefit from the potential for increased resources and project advancement.
• Customers may benefit from the potential development of new treatments.

Next Steps

• RespireRx will work with ATT India to prepare and submit the Phase II grant application by August 28, 2024.
• The company will also work with ATT US to prepare for potential TABA services if the grant is awarded.
• RespireRx will need to manage the project and comply with all NIH requirements if the grant is received.

Key Dates

Keywords

NIH, SBIR, STTR, grant, funding, GABAkines, pharmaceuticals, regulatory, intellectual property, accounting